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Background: Radiotherapy is an important treatment strategy for head and neck cancers. Tumor hypoxia and
repopulation adversely affect the radiotherapy outcome. Accordingly, fractionated radiotherapy with dose escalation or
altered fractionation schedule is used to prevent hypoxia and repopulation. 18F-fluoromisonidazole (FMISO) and
18F-fluorothymidine (FLT) are noninvasive markers for assessing tumor hypoxia and proliferation, respectively. Thus, we
evaluated the dynamic changes in intratumoral hypoxic and proliferative states following radiotherapy using the dual
tracers of 18F-FMISO and 3H-FLT, and further verified the results by immunohistochemical staining of pimonidazole
(a hypoxia marker) and Ki-67 (a proliferation marker) in human head and neck cancer xenografts (FaDu).
Methods: FaDu xenografts were established in nude mice and assigned to the non-radiation-treated control and two
radiation-treated groups (10- and 20-Gy). Tumor volume was measured daily. Mice were sacrificed 6, 24, and 48 hrs and
7 days after radiotherapy. 18F-FMISO, and 3H-FLT and pimonidazole were injected intravenously 4 and 2 hrs before
sacrifice, respectively. Intratumoral 18F-FMISO and 3H-FLT levels were assessed by autoradiography. Pimonidazole and
Ki-67 immunohistochemistries were performed.
Results: In radiation-treated mice, tumor growth was significantly suppressed compared with the control group, but
the tumor volume in these mice gradually increased with time. Visual inspection showed that intratumoral 18F-FMISO
and 3H-FLT distribution patterns were markedly different. Intratumoral 18F-FMISO level did not show significant changes
after radiotherapy among the non-radiation-treated control and radiation-treated groups, whereas 3H-FLT level
markedly decreased to 59 and 45% of the non-radiation-treated control at 6 hrs (p < 0.0001) and then gradually
increased with time in the 10- and 20-Gy-radiation-treated groups. The pimonidazole-positive hypoxic areas were
visually similar in both the non-radiation-treated control and radiation-treated groups. No significant differences were
observed in the percentage of pimonidazole-positive cells and Ki-67 index.
Conclusion: Intratumoral 18F-FMISO level did not change until 7 days, whereas 3H-FLT level markedly decreased at 6 hrs
and then gradually increased with time after a single dose of radiotherapy. The concomitant monitoring of dynamic
changes in tumor hypoxia and proliferation may provide important information for a better understanding of tumor
biology after radiotherapy and for radiotherapy planning, including dose escalation and altered fractionation schedules.
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Over the past few decades, the preferred treatment strat-
egies for squamous cell carcinoma of the head and neck
have gradually shifted from surgery to organ-preservation
approaches such as radiotherapy with or without chemo-
therapy. Tumor hypoxia and accelerated tumor prolifera-
tion are important factors that adversely affect the efficacy
of radiotherapy [1-3]. Accordingly, in recent radiotherapy
strategies, dose escalation and altered fractionation sched-
ules are widely applied to prevent tumor hypoxia and ac-
celerated tumor proliferation [2]. Head and neck tumors
are highly hypoxic in nature and also show accelerated
proliferation of clonogenic tumor cells during the course
of treatment, which hinders the efficacy of radiotherapy
and leads to locoregional treatment failure [4,5]. Particu-
larly in the case of moderately or poorly radiosensitive
cancers, how they respond to radiotherapy remains a
clinical dilemma for medical professionals. Sometimes
there is no good outcome even after an entire session of
radiotherapy.
Better understanding of the tumor microenvironment
such as the tumor hypoxic state and proliferative activity
allows a better optimal individualized plan for radiother-
apy (such as dose escalation or altered fractionation
schedule). For this purpose, numerous immunohisto-
chemical or immunofluorescence microscopy techniques
have been established. However, biopsy or excised tissue
samples are required for all these techniques, and collec-
tion of such samples is invasive and prone to sampling
error. Recently, the exploration of tumor hypoxic and
proliferative states has shifted to diagnostic imaging
owing to the rapidly developing field of molecular im-
aging. Specific biomarker probes can be administered
and visualized in vivo with the aid of functional imaging
modalities such as PET. 18F-Fluoromisonidazole (FMISO)
and 18F-fluorothymidine (FLT) are widely used for nonin-
vasive imaging of tumor hypoxia and tumor proliferation,
respectively [6-13]. FMISO is reduced and trapped in hyp-
oxic cells, and reflects tumor hypoxia. The proliferation
marker FLT reflects thymidine kinase 1 (TK1) activity,
which is extremely sensitive to ionizing radiation, and
changes in FLT uptake level directly reflect the biological
effect of radiation therapy [14,15].
Intratumoral hypoxia or proliferative activity following
radiotherapy was evaluated in several studies using
FMISO or FLT [7-13]. There have been no studies, how-
ever, in which the dynamic changes in intratumoral hyp-
oxic state and proliferative activity after single-dose
radiotherapy were simultaneously evaluated using the
dual tracers of FMISO and FLT. Such investigations may
provide important information for a better understand-
ing of tumor biology after radiotherapy and for radio-
therapy planning, including dose escalation and altered
fractionation schedules, particularly in moderately orpoorly radiosensitive head and neck carcinoma. Thus, in
this study, we simultaneously evaluated the dynamic
changes in intratumoral hypoxic and proliferative states
using FMISO and FLT, and further verified the results
by immunohistochemical staining of pimonidazole and
Ki-67 after a single dose of radiation of human head and
neck cancer xenografts using a moderately radiosensitive
cancer cell line, FaDu.
Methods
Radiopharmaceuticals
18F-FMISO was obtained from the Hokkaido University
Hospital Cyclotron Facility, which was synthesized as
previously described [16-18]. [Methyl-3H (N)]-3′-fluoro
3′-deoxythymidine (3H-FLT) (specific activity, 74–370
GBq/mmol) was purchased from Moravek Biochemicals
Inc., CA.
Xenograft model and irradiation
All experimental protocols were approved by the La-
boratory Animal Care and Use Committee of Hokkaido
University (approval number 13–0057) and were per-
formed according to the Guidelines for Animal Experi-
ments at the Graduate School of Medicine, Hokkaido
University. Nine-week-old male BALB/c athymic nude
mice (supplied by Japan SLC, Inc., Hamamatsu, Japan)
were used in all experiments. A human head and neck
cancer xenograft model was established in mice using
the human head and neck squamous cell carcinoma cell
line FaDu. FaDu cells (5 × 106 cells/0.1 ml) were inocu-
lated subcutaneously into the right flank of each mouse,
as previously described [12].
When the tumors reached 12–14 mm in diameter,
the mice were randomly assigned to three groups: one
non-radiation-treated control group (Control) and two
radiation-treated groups at 10 and 20 Gy (Treat-10 Gy
and Treat-20 Gy) (n = 19 for each group) (Figure 1).
Data were collected at four time points for each group
(6, 24, and 48 hrs, and 7 days from irradiation to kill-
ing; n = 5 for the time points of 6, 24, and 48 hrs and
n = 4 for the time points of 7 days). A tumor growth curve
was derived from the animals assigned to day 7 in each
group. Tumor size was measured every day from the start
of the radiation treatment and tumor volume was calcu-
lated using the following formula: π/6 × largest diameter ×
(smallest diameter)2.
In the radiation-treated groups, tumors were irradiated
at a single dose of 10 or 20 Gy using an X-ray generator
(MBR- 1520R-3; Hitachi, Tokyo, Japan) at a dose rate of
1.69 Gy/min, as previously described [12].
Dual tracer (18F-FMISO and 3H-FLT) ARG study
Two hours after 18F-FMISO (18.5 MBq) injection, the mice
were intravenously injected with 3H-FLT (0.185 MBq) and
Figure 1 Experimental protocol of this study.
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Two hours after 3H-FLT and pimonidazole injections,
these mice were sacrificed and the tumors were excised.
The excised tumors were then embedded in Tissue-Tek
medium (Sakura Finetechnical Co., Ltd., Tokyo, Japan)
with a calf muscle section and frozen in isopentane/dry
ice. Serial cross sections of 10 μm (for autoradiographic
exposure) or 5 μm (immunohistochemical staining) thick-
ness were immediately cut and thaw-mounted on a glass
slide.
The distribution of each tracer in the tumor tissue was
determined by dual-tracer ARG [19]. Briefly, the same
cryostat cross sections were exposed twice to phosphor
imaging plates (Fuji Imaging Plate BAS-SR 2025 for 18F
and BAS-TR 2025 for 3H, Fuji Photo Film Co., Ltd.,
Japan) together with a set of calibrated standards [20].
The first autoradiographic exposure was performed over-
night to detect the radioactivity of 18F-FMISO. To allow
the decay of 18F activity, the second exposure was started
1 week later to visualize the distribution of 3H-FLT. The
second exposure required 5 weeks. After each exposure,
the imaging plates were scanned using a Fuji Bio-imaging
Analyzer FLA-7000 (Fuji Photo Film Co., Ltd., Minato-ku,
Tokyo, Japan), and the images obtained were analyzed
using image analysis software Multi Gauge (Ver. 3.0, Fuji
Photo Film Co., Ltd., Japan).
For the quantitative evaluation of 18F-FMISO and 3H-
FLT radioactivities, ROIs were placed to cover the entire
tumor tissue and muscles on each ARG image withreference to the H&E sections. 18F-FMISO or 3H-FLT
radioactivity in each ROI was separately recorded and
calculated as percentage injected dose per gram (%ID/g)
and normalized with body weight [(%ID/g) × kg], as pre-
viously described [12,20,21].
Immunohistochemical staining
Frozen sections of the tumor were stained for pimoni-
dazole (a hypoxia marker) and Ki-67 (a proliferation
marker) to assess hypoxia and proliferation, respectively.
The immunohistochemical staining of pimonidazole
(HypoxyprobeTM-1, HIP Inc.) was performed using a
monoclonal antibody (rabbit IgG1, HIP Inc.) and that
of Ki-67 was performed using a monoclonal rabbit anti-
human Ki-67 antibody (clone SP6) (Thermo Fisher Scien-
tific, CA, USA). For the quantitative analysis of hypoxia,
the percentage of the area positively stained by the anti-
pimonidazole antibody in the entire tumor cross section
was calculated as the hypoxic fraction (%pimonidazole-
positive area) using Image J. For the quantitative analysis
of tumor proliferation, the Ki-67 labeling index, that is,
the percentage of the number of Ki-67-positive nuclei to
the total number of nuclei, was used. The number of Ki-
67-positive nuclei and the total number of nuclei were
counted under a microscope field (x400 magnification,
0.644 mm2 per field) using Image J. H&E staining was also
performed.
Statistical analyses
All statistical analyses were performed using Stat View
version 5.0 (SAS Institute, Inc.). All values are expressed
as mean ± SD (standard deviation). One-factor repeated
measures analysis of variance (ANOVA) was carried out
to compare tumor volume among the non-radiation-
treated control and radiation-treated (10 and 20 Gy)
groups. Two-way factorial ANOVA was performed to
compare intratumoral 18F-FMISO level, intratumoral
3H-FLT uptake level, hypoxic fraction and percentage of
Ki-67 labeling index with time among the three groups.
One-way ANOVA followed by a Bonferroni post-hoc
test was used to assess the significance of difference
among the three groups at each time point and among
the time points in each group for tumor volume and
intratumoral 3H-FLT uptake level. Linear regression
analysis was performed to determine the correlation
between the tracer uptake levels of 18F-FMISO and




The changes in tumor volume are shown in Figure 2. In
the non-radiation-treated control group, tumor volume
increased with time. Compared with the control group,
Figure 2 Growth curves of tumors in non-radiation-treated
control and 10- and 20-Gy radiation-treated mice. Data are
expressed as mean ± SD. *p < 0.01 for both Control vs Treat-10 Gy
and Control vs Treat-20 Gy.
Figure 3 Representative merged images of 18F-FMISO and
3H-FLT ARG. Red represents 18F-FMISO distribution and green
represents 3H-FLT distribution. The dotted line represents the outline
of muscle tissue.
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treated with 10 and 20 Gy radiation, but the tumor vol-
ume in these mice gradually increased with time. A
significant difference in tumor volume was observed
between the non-radiation-treated control and the
radiation-treated groups on day 7 (p < 0.01 for both
Control vs Treat-10 Gy and Control vs Treat-20 Gy),
whereas no statistically significant difference was ob-
served between the two radiation-treated groups. No sig-
nificant differences in tumor volume were noted among
the three groups until day 6.
Visual and quantitative analysis of 18F-FMISO and 3H-FLT
ARG image
Figure 3 shows the representative merged images of 18F-
FMISO and 3H-FLT ARG. In the non-radiation-treated
control group, 18F-FMISO was distributed mostly in the
central part of the tumor tissue at all time points. The
10- and 20-Gy-radiation-treated groups also showed a
similar 18F-FMISO distribution pattern to the control
group (Figure 3). On the other hand, 3H-FLT was dis-
tributed mostly in the peripheral part of the tumor tissue
in both the non-radiation-treated control and radiation-
treated groups, and 3H-FLT uptake level was low at
6 hrs compared with the control group, and then grad-
ually increased with time, 24 and 48 hrs, and day 7 after
10 and 20 Gy radiation treatment (Figure 3).
Figure 4 shows the quantitative analysis of intratu-
moral 18F-FMISO and 3H-FLT uptake level and theircorrelation. In the non-radiation-treated control group,
the 18F-FMISO level slightly increased with time, but the
differences were not significant. No significant differ-
ences were observed among the non-radiation-treated
control group and the radiation-treated groups at any
time points. The 18F-FMISO levels in the tumors were
0.06 ± 0.03, 0.05 ± 0.01, and 0.04 ± 0.04 [(%ID/g) × kg] at
6 hrs, 0.06 ± 0.01, 0.06 ± 0.01, and 0.06 ± 0.025 [(%ID/g) ×
kg] at 24 hrs, 0.07 ± 0.02, 0.07 ± 0.01, and 0.07 ± 0.02
[(%ID/g) × kg] at 48 hrs, and 0.08 ± 0.02, 0.07 ± 0.01, and
0.06 ± 0.01 [(%ID/g) × kg] on day 7 in the non-radiation-
treated control and the 10- and 20-Gy-radiation-treated
groups, respectively (Figure 4A). On the other hand,
intratumoral 3H-FLT uptake level significantly decreased
to 59 and 45% (p < 0.0001) at 6 hrs in the 10- and 20-
Gy-radiation-treated groups compared with the non-
radiation-treated control group. Thereafter, intratumoral
3H-FLT uptake level gradually increased with time in both
the radiation-treated groups, and the 3H-FLT uptake levels
on day 7 were significantly higher than those at 6 hrs in
the corresponding radiation-treated groups. The intratu-
moral 3H-FLT uptake levels were 64 and 50% at 24 hrs
(p < 0.01 for both), 64 and 59% at 48 hrs (p < 0.01 for
both), and 81 and 81% on day 7 (p =NS for both) in the
mice treated at 10 and 20 Gy, respectively, compared with
the non-radiation-treated control mice (Figure 4B). The
intratumoral 3H-FLT uptake levels in the tumors were
5.11 ± 0.62, 3.06 ± 0.42, and 2.34 ± 0.52 [(%ID/g) × kg] at
6 hrs, 5.72 ± 0.90, 3.70 ± 0.88, and 2.86 ± 0.42 [(%ID/g) ×
kg] at 24 hrs, 6.56 ± 1.63, 4.22 ± 0.53, and 3.84 ± 0.94
[(%ID/g) × kg] at 48 hrs, and 6.11 ± 0.86, 5.08 ± 0.95, and




Figure 4 Quantitative analysis of intratumoral (A) 18F-FMISO and (B) 3H-FLT uptake levels by ARG and (C) regression analysis of the
uptake levels of 18F-FMISO and 3H-FLT. Data are expressed as mean ± SD. *p < 0.01 and **p < 0.0001 for both Control vs Treat-10 Gy and
Control vs Treat-20 Gy. †p < 0.001, 6 hrs vs day 7 for each group radiation-treated with 10 and 20 Gy.
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groups, respectively (Figure 4B). The relationship be-
tween 18F-FMISO and 3H-FLT uptake levels is shown in
Figure 4C. No significant correlation was observed be-
tween the two tracer distributions (r = 0.081, p = 0.54).
Immunohistochemical staining
Representative images and the quantitative analysis of
hypoxia (%pimonidazole-positive cells) by pimonidazole(A)
Figure 5 Microscopy images and quantitative analysis of hypoxia. (A)
(A) Representative images of pimonidazole staining (brown staining in pimIHC are shown in Figure 5. The pimonidazole-positive
hypoxic areas were visually similar in both the non-
radiation-treated control and radiation-treated groups
(Figure 5A). The hypoxic fractions in tumors were 12.0 ±
2.6, 11.6 ± 2.7, and 9.8 ± 1.4% at 6 hrs, 12.1 ± 1.8, 12.3 ±
1.8, and 11.6 ± 0.77% at 24 hrs, 10.07 ± 3.0, 11.49 ± 3.0,
and 10.65 ± 2.1% at 48 hrs, and 10.8 ± 3.6, 9.23 ± 0.86, and
10.46 ± 2.6% on day 7 in the non-radiation-treated control
and the 10- and 20-Gy radiation-treated groups, respectively(B)
Microscopy images and (B) quantitative analysis of hypoxia.
onidazole-positive cells). (B) Mean hypoxic fraction ± SD.
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the percentage of pimonidazole-positive cells among the
three groups (F = 0.36; p = 0.69) at various time points
(F = 1.43; p = 0.24).
Figure 6 shows the representative images and the
quantitative evaluation of Ki-67 labeling index by IHC.
No significant differences were observed in the percent-
age of Ki-67 labeling index with time and among the
three groups (Figure 6A). The Ki-67 labeling indices in
tumor tissues were 60.7 ± 10.8, 60.3 ± 13.4, and 59.1 ±
19.4% at 6 hrs, 57.7 ± 12.3, 54.8 ± 10.9, and 55.5 ± 16.2%
at 24 hrs, 58.2 ± 23.1, 58.7 ± 14.6, and 54.2 ± 14.3% at
48 hrs, and 63.0 ± 20.4, 60.6 ± 15.6, and 59.3 ± 11.9% on
day 7 in the non-radiation-treated control and the 10- and
20-Gy radiation-treated groups, respectively (Figure 6B).
Discussion
The major findings of this dual-tracer study are as fol-
lows. Intratumoral 18F-FMISO level did not show any
significant dynamic changes with time after single-dose
radiotherapy among the non-radiation-treated control
and radiation-treated groups. On the other hand, intra-
tumoral 3H-FLT uptake level significantly decreased at
6 hrs and then gradually increased with time in the
radiation-treated groups (Figures 3, 4A, B). In the visual
analysis of intratumoral 18F-FMISO and 3H-FLT ARG
images, 18F-FMISO was distributed mostly in the central
part of the tumor tissue, whereas 3H-FLT was distrib-
uted in the peripheral part of the tumor tissue in both
the non-radiation-treated control and radiation-treated
groups (Figure 3). In the radiation-treated groups, tumor
growth was suppressed compared with that in the non-
radiation-treated control group, but tumor volume in
these mice gradually increased with time (Figure 2). The
hypoxia fraction determined by pimonidazole IHC also
showed no significant changes with time after single-Figure 6 Microscopy images and quantitative analysis of Ki-67 labelin
labeling index. (A) Representative images of Ki-67 staining (brown stainingdose radiotherapy among the non-radiation-treated con-
trol and radiation-treated groups (Figure 5A, B). The
tumor proliferation marker, Ki-67 labeling index, did not
show significant changes among the non-radiation-treated
control and radiation-treated groups (Figure 6A, B). These
findings indicate that radiation-induced intratumoral hyp-
oxic and proliferative changes differed. These two factors
showed different behaviors following radiotherapy until
7 days in the FaDu xenografts. Radiation-induced lethal/
sublethal cellular damage followed by DNA repair and re-
distribution [22,23] may underlie the dynamic changes in
proliferation activity, whereas reoxygenation after a single-
dose radiotherapy did not occur in FaDu xenografts.
Several studies have shown that reoxygenation of tu-
mors occurs 4–10 hrs (early stage) and 1 or 2 days (late
stage) after single-dose radiotherapy [3,24,25]. After
radiotherapy, transient changes caused by cell death are
likely to occur during the oxygenation of surviving cells.
Owing to the increase in oxygen levels and therefore an
increase in radiosensitivity of a subset of tumor cell
population [3,25]. Therefore in our study, first 18F-
FMISO level was expected to decrease in concert with
the attenuation of tumor hypoxia (%pimonidazole-posi-
tive area decrease) following radiotherapy as radiation-
induced reoxygenation. Early detection of such changes
may lead to the decrease in radiotherapy dose and total
time in the fractionated radiotherapy schedule, which
can reduce the undesirable side effects of radiotherapy.
However, our data showed that tumor volume in the
treated mice did not decrease following radiotherapy,
and the intratumoral hypoxic state also did not change
after the single dose of radiotherapy until 7 days. The
hypoxia marker pimonidazole IHC also showed no sig-
nificant changes among the non-radiation treated con-
trol and radiation-treated groups after radiotherapy.
These findings may indicate that a single-dose 10- org index. (A) Microscopy images and (B) quantitative analysis of Ki-67
in Ki-67 positive cells). (B) Mean Ki-67 labeling index ± SD.
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FaDu xenografts. FaDu cells are undifferentiated human
hypopharyngeal squamous cell carcinoma cells that are
characterized by moderate radiosensitivity [26,27]. Kasten-
Pisula et al. [28] showed that the apoptotic changes occur-
ring in FaDu cells are very minimal and no changes were
observed after a single dose of radiation over time. Less ra-
diosensitivity and less apoptotic response to radiotherapy
of the FaDu cells would be the possible reasons for the ab-
sence of changes in the hypoxia state after a single dose of
radiotherapy until 7 days in our study. Changes in the
tumor hypoxic state depend on many individualized
tumor properties, including the number of cells affected
by reoxygenation, the degree of oxygen increase, and the
timing or progression of this effect during therapy [24,25].
For these aggressive and less radiosensitive cell lines such
as FaDu, further radiotherapy fractionation might induce
reoxygenation. Petersen et al. [29] showed that significant
reoxygenation (hypoxic changes) occurs after 12 days of
fractionated radiotherapy (3 Gy/12f/12d = total 36 Gy) in
FaDu xenografts. Another study [30] also showed that the
mean pO2 (Oxylab pO2 system) significantly increased
after 2 weeks of accelerated fractionated radiotherapy
(total dose of 40 Gy). All these results also partially sup-
port the findings of our study.
On the other hand, the intratumoral 3H-FLT uptake
level in this FaDu xenograft significantly decreased at an
early time point (6 hrs) and then gradually but signifi-
cantly increased with time, showing the dynamic prolif-
erative changes as in our previous study [12]. FLT is a
substrate of TK1, and FLT uptake positively correlates
with cell growth and TK1 activity. The rapid decrease in
FLT uptake level observed may be due to a rapid de-
crease in TK1 activity after radiation treatment [11,14].
After radiotherapy, the strategy to deal with damaged
DNA can be divided in to three components in eukary-
otes: recognition of damaged DNA; a period of damage
assessment; and the implementation of the appropriate
response, namely, DNA repair and redistribution of cells
among the cell-cycle phases or cell death [22]. These
DNA repair and redistribution of cells among the cell-
cycle phase might lead to cellular proliferation, which
may increase TK1 activity and may be reflected by the
increase in intratumoral FLT uptake level with time after
a single dose of radiotherapy, as we discussed in our pre-
vious study [12]. In our study, we found the suppression
of tumor growth after radiation treatment compared
with the non-radiation-treated control group. However,
there were no significant changes in the Ki-67 index
among the non-radiation-treated control and radiation-
treated groups in our study. Ki-67 is a nuclear protein
and expressed during the late G1, S, G2, and M phases
of the cell cycle. Radiotherapy causes G2/M phase arrest
and the arrested cells during the cell cycle also containKi-67 even though they are not actively proliferating, as
we discussed in our previous study [12].
Human head and neck tumors showed different hyp-
oxic and proliferative patterns after radiotherapy, even
when they have the same histological feature [31]. Thus,
evaluation of dynamic changes in intratumoral hypoxic
and proliferative states using the dual tracers FMISO
and FLT is important. In our study, we used the less ra-
diosensitive cell line FaDu and found no changes in
intratumoral 18F-FMISO level. On the other hand, the
intratumoral 3H-FLT uptake level significantly decreased
at 6 hrs and then gradually increased with time. These
findings indicate that single-dose 10- or 20-Gy radio-
therapy may not affect the hypoxic state but still affect
proliferative activity in this aggressive and less radiosen-
sitive cell line. In our case, further radiotherapy fraction-
ation may cause reoxygenation (decrease in 18F-FMISO
level) and delay the gradual enhancement of proliferation.
In this study, no significant hypoxic changes were found
between 10- and 20-Gy radiation doses. Therefore, further
radiotherapy fractionation (10 Gy or less) without dose es-
calation will be appropriate for this situation. If no marked
changes occur after further radiotherapy fractionation, an
immediate shift to a combination therapy or surgical pro-
cedures would be the treatment of choice. Thus, early
evaluation of dynamic changes in intratumoral hypoxic
and proliferative states by a dual-tracer study may pro-
vide important information for a better understanding of
tumor biology after radiotherapy and for radiotherapy
planning including dose escalation and altered fraction-
ation schedules.
The limitation of our study was that only one tumor
model, i.e., a moderately radiosensitive cancer cell line,
was used to evaluate the dynamic changes in the tumor
microenvironment (intratumoral hypoxic state and prolif-
erative activity) after a single dose of radiation using dual
tracers of 18F-FMISO and 3H-FLT. Various cancer cell
lines, such as radiosensitive and radioresistant cancer cell
lines should be used to confirm our present results.
Conclusions
Our animal model showed no dynamic changes in intra-
tumoral 18F-FMISO level after single-dose radiotherapy.
On the other hand, 3H-FLT uptake level significantly de-
creased at 6 hrs and then gradually increased with time.
These findings indicate that radiation-induced intratu-
moral hypoxic and proliferative changes differed and
these two factors show different behaviors until 7 days
in the FaDu xenografts. Thus, concomitant monitoring
of dynamic changes in intratumoral hypoxic states and
proliferative activity may provide important information
for a better understanding of tumor biology after radio-
therapy and for radiotherapy planning, including dose
escalation and altered fractionation schedules.
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